Emad Ibrahim

857 total citations
8 papers, 147 citations indexed

About

Emad Ibrahim is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Emad Ibrahim has authored 8 papers receiving a total of 147 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 2 papers in Hematology. Recurrent topics in Emad Ibrahim's work include Cancer therapeutics and mechanisms (2 papers), Neutropenia and Cancer Infections (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Emad Ibrahim is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), Neutropenia and Cancer Infections (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Emad Ibrahim collaborates with scholars based in United States, Australia and Poland. Emad Ibrahim's co-authors include Serge Braun, W. King Engel, Valerie Askanas, James Wang, James R. Berenson, Kyle A. Udd, Jonathan Treisman, Regina A. Swift, Tanya M. Spektor and Н. В. Коваленко and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Emad Ibrahim

8 papers receiving 143 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emad Ibrahim United States	7	65	49	18	15	15	8	147
Jean-Pierre David Germany	8	52 0.8×	98 2.0×	15 0.8×	14 0.9×	6 0.4×	9	181
L. Torres Spain	8	44 0.7×	52 1.1×	19 1.1×	6 0.4×	26 1.7×	16	187
Bernard S. Buetow United States	8	114 1.8×	76 1.6×	13 0.7×	12 0.8×	20 1.3×	13	228
Caroline S. Kim United States	8	53 0.8×	142 2.9×	50 2.8×	17 1.1×	10 0.7×	11	313
Hyuk Jai Shin South Korea	9	49 0.8×	67 1.4×	9 0.5×	35 2.3×	15 1.0×	23	243
Fatemeh Alikarami‬ Iran	9	32 0.5×	107 2.2×	28 1.6×	10 0.7×	13 0.9×	15	179
Lianna J. Marks United States	7	39 0.6×	34 0.7×	31 1.7×	40 2.7×	13 0.9×	21	137
Eloísa Riva Uruguay	7	38 0.6×	64 1.3×	47 2.6×	17 1.1×	16 1.1×	39	161
Sonja Rothweiler Switzerland	7	69 1.1×	61 1.2×	10 0.6×	9 0.6×	37 2.5×	8	256

Countries citing papers authored by Emad Ibrahim

Since Specialization

Citations

This map shows the geographic impact of Emad Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emad Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emad Ibrahim more than expected).

Fields of papers citing papers by Emad Ibrahim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emad Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emad Ibrahim. The network helps show where Emad Ibrahim may publish in the future.

Co-authorship network of co-authors of Emad Ibrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Emad Ibrahim. A scholar is included among the top collaborators of Emad Ibrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emad Ibrahim. Emad Ibrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Ailawadhi, Sikander, Patrick J. Stiff, Emad Ibrahim, et al.. (2021). CLR 131 (Iopofosine I-131) Treatment in Triple Class Refractory and Beyond Multiple Myeloma Patients: Preliminary Efficacy and Safety Results from the Phase 2 Clover-1 Trial. Blood. 138(Supplement 1). 1652–1652. 7 indexed citations

Blayney, Douglas W., Qingyuan Zhang, Jifeng Feng, et al.. (2020). Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non–Small Cell Lung Cancer. JAMA Oncology. 6(11). e204429–e204429. 25 indexed citations

Ailawadhi, Sikander, Patrick J. Stiff, Emad Ibrahim, et al.. (2019). Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 134(Supplement_1). 144–144. 4 indexed citations

Vacirca, Jeffrey, Arlene Chan, Zsuzsanna Pápai, et al.. (2018). An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer. Cancer Medicine. 7(5). 1660–1669. 10 indexed citations

Ibrahim, Emad, Debu Tripathy, Mary Wilkinson, et al.. (2017). Abstract CT128: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients (pts) with HER2+ early-stage breast cancer (eBC): the CONTROL trial. Cancer Research. 77(13_Supplement). CT128–CT128. 15 indexed citations

Wang, James, Kyle A. Udd, Regina A. Swift, et al.. (2016). Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy. Supportive Care in Cancer. 24(7). 3105–10. 28 indexed citations

Vergote, Ignace, Agustin A. García, John P. Micha, et al.. (2013). Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial Ovarian Cancer. Journal of Clinical Oncology. 31(32). 4060–4066. 34 indexed citations

Braun, Serge, Valerie Askanas, W. King Engel, & Emad Ibrahim. (1993). Long‐Term Treatment with Glucocorticoids Increases Synthesis and Stability of Junctional Acetylcholine Receptors on Innervated Cultured Human Muscle. Journal of Neurochemistry. 60(5). 1929–1935. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact